Hybrid coating for medical devices
First Claim
1. A coating composition for rendering substrates bio-compatible and delivering therapeutic agents in vivo comprising:
- i. an aqueous dispersion or emulsion of an organic acid functional group-containing polymer and an excess of a polyfunctional crosslinker which is reactive with said organic acid functional groups of said polymer;
ii. a therapeutic agent dispersed within said aqueous dispersion or emulsion, said therapeutic agent being substantially non-reactive with said polymer or said crosslinker; and
iii. an aqueous solution or dispersion of an organic acid functional group-containing bio-active agent or equivalent thereof, said polymer covalently bonded to said organic acid functional groups on said bio-active agent through said unreacted excess polyfunctional crosslinker.
4 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are hybrid coatings for implantable medical devices. Such coatings include a first layer of an aqueous dispersion or emulsion of an organic acid functional group containing polymer, a crosslinker and a therapeutic agent dispersed therein. The coating also includes a second layer of an aqueous solution or dispersion of an organic acid functional group-containing bio-active agent. The hybrid coatings are especially suited for preventing restenosis of endoprostheses by the combined action of the therapeutic agent and the bio-active agent. Methods of making and using devices coated with such compositions are also provided.
361 Citations
34 Claims
-
1. A coating composition for rendering substrates bio-compatible and delivering therapeutic agents in vivo comprising:
-
i. an aqueous dispersion or emulsion of an organic acid functional group-containing polymer and an excess of a polyfunctional crosslinker which is reactive with said organic acid functional groups of said polymer;
ii. a therapeutic agent dispersed within said aqueous dispersion or emulsion, said therapeutic agent being substantially non-reactive with said polymer or said crosslinker; and
iii. an aqueous solution or dispersion of an organic acid functional group-containing bio-active agent or equivalent thereof, said polymer covalently bonded to said organic acid functional groups on said bio-active agent through said unreacted excess polyfunctional crosslinker. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
-
20. A medical device having a coating on at least a portion of a surface thereof, said coating comprising:
-
i. a first layer formed from (a) an aqueous dispersion or emulsion of an organic acid functional group-containing polymer, (b) an excess of a polyfunctional crosslinker which is reactive with said organic acid groups and (c) a therapeutic agent dispersed within said aqueous dispersion or emulsion, wherein said therapeutic agent is substantially non-reactive with (a) or (b); and
ii. a second coating of an aqueous solution or dispersion containing an organic acid functional group-containing bio-active agent or equivalent thereof, said first coating covalently bonded to said second coating through said excess crosslinker and said organic acid functional groups on said bio-active coating, wherein said therapeutic agent is releasable from said first coating and said bio-active agent substantially remains on a surface of said medical device. - View Dependent Claims (21, 22, 23, 24, 25, 26, 27, 28, 29)
-
-
30. A multi-layer coating composition for rendering substrates bio-compatible and delivering therapeutic agents in vivo comprising a reaction product of:
-
i. a first layer comprising an aqueous polymer dispersion or emulsion, a crosslinker and a therapeutic agent physically dispersed within said dispersion or emulsion, wherein said therapeutic agent is releasable from said first layer and is substantially non-reactive with said polymer or said crosslinker; and
ii. a second layer comprising an aqueous solution or dispersion containing a bio-active agent, wherein said polymer of said first layer is covalently bonded to said bio-active agent through said crosslinker. - View Dependent Claims (31, 32, 33, 34)
-
Specification